BIOMEA FUSION INC. - COMMON STOCK
3.7450
07-February-25 16:45:00
15 minutes delayed
Stocks
-0.3750
-9.10%
Today's range
3.7050 - 4.1500
ISIN
N/A
Source
NASDAQ
-
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 Jan 2025 09:00:00 By Nasdaq GlobeNewswire
-
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
07 Jan 2025 09:00:00 By Nasdaq GlobeNewswire
-
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire
-
17 Dec 2024 08:10:00 By Nasdaq GlobeNewswire
-
16 Dec 2024 18:15:01 By Nasdaq GlobeNewswire
-
12 Dec 2024 17:02:21 By Nasdaq GlobeNewswire
-
09 Dec 2024 16:01:00 By Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2024 16:05:00 By Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2024 16:05:51 By Nasdaq GlobeNewswire
-
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
29 Oct 2024 16:46:08 By Nasdaq GlobeNewswire
-
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
21 Oct 2024 09:00:29 By Nasdaq GlobeNewswire
-
15 Oct 2024 16:05:19 By Nasdaq GlobeNewswire
-
07 Oct 2024 09:00:41 By Nasdaq GlobeNewswire
-
01 Oct 2024 09:00:01 By Nasdaq GlobeNewswire
-
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
26 Sep 2024 14:00:57 By Nasdaq GlobeNewswire
-
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2024 16:05:20 By Nasdaq GlobeNewswire
-
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
31 Jul 2024 16:05:22 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >